HLB Group Chairman Jin Yang-gon announced on the 7th that he purchased 110,000 shares of HLB Innovation in the market. This follows Jin's additional purchase after acquiring 100,000 shares of HLB Innovation during trading on the 16th of last month.
In this regard, the company explained that HLB Innovation's confidence in the value of the chimeric antigen receptor (CAR)-T therapies from Verismo Therapeutics, which was incorporated as a 100% subsidiary at the end of last year, played a role. CAR-T therapies are a next-generation cancer treatment that genetically modifies T cells, a type of immune cell, to target only cancer cells.
According to the company, Verismo is currently conducting a Phase 1 clinical trial in the United States targeting solid tumors and blood cancers based on its innovative KIR-CAR platform. The company stated, "We expect HLB Innovation's future corporate value to rise significantly, with CAR-T therapies as a growth driver."
As the group's CEO, Jin has consistently purchased shares of affiliate companies to improve the value of undervalued listed companies and ensure sustainable growth. Since November of last year, he has made multiple purchases totaling 425,645 shares of HLB Genex. He has also continued to buy shares of HLB Therapeutics and HLB bioStep.